Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Neurotoxicology ; 54: 65-71, 2016 05.
Article in English | MEDLINE | ID: mdl-27018513

ABSTRACT

Environmental lead (Pb) exposure and prenatal stress (PS) are co-occurring risk factors for impaired cognition and other disorders/diseases in adulthood and target common biological substrates in the brain. Sex-dependent differences characterize the neurochemical and behavioral responses of the brain to Pb and PS and sexually dimorphic histone modifications have been reported to occur in at-risk brain regions (cortex and hippocampus) during development. The present study sought to examine levels and developmental timing of sexually dimorphic histone modifications (i.e., H3K9/14Ac and H3K9Me3) and the extent to which they may be altered by Pb±PS. Female C57/Bl6 mice were randomly assigned to receive distilled deionized drinking water containing 0 or 100ppm Pb acetate for 2 months prior to breeding and throughout lactation. Half of the dams in each group were exposed to restraint stress (PS, three restraint sessions in plastic cylindrical devices 3×/day at for 30min/day (1000, 1300, and 1600h)) from gestational day 11-19 or no stress (NS). At delivery (PND0) and postnatal day 6 (PND6), pups were euthanized and frontal cortex and hippocampus were removed, homogenized, and assayed for levels of H3K9/14Ac and H3K9Me3. Sex-dependent differences in both levels of histone modifications as well as the developmental trajectory of changes in these levels were observed in both structures and these parameters were differentially affected by Pb±PS in a sex and brain-region-dependent manner. Disruptions of these epigenetic processes by developmental Pb±PS may underlie some of the sex-dependent neurobehavioral differences previously observed in these animals.


Subject(s)
Hippocampus/drug effects , Histones/metabolism , Lead/toxicity , Prefrontal Cortex/drug effects , Prenatal Exposure Delayed Effects/pathology , Sex Characteristics , Age Factors , Animals , Animals, Newborn , Body Weight/drug effects , Female , Hippocampus/growth & development , Lead/blood , Litter Size/drug effects , Male , Mice , Mice, Inbred C57BL , Prefrontal Cortex/growth & development , Pregnancy , Prenatal Exposure Delayed Effects/blood , Protein Processing, Post-Translational/drug effects , Time Factors
2.
PLoS One ; 10(12): e0143351, 2015.
Article in English | MEDLINE | ID: mdl-26629687

ABSTRACT

BACKGROUND: Preclinical and clinical studies have previously shown that systemic administration of GM1 ganglioside has neuroprotective and neurorestorative properties in Parkinson's disease (PD) models and in PD patients. However, the clinical development of GM1 for PD has been hampered by its animal origin (GM1 used in previous studies was extracted from bovine brains), limited bioavailability, and limited blood brain barrier penetrance following systemic administration. OBJECTIVE: To assess an alternative therapeutic approach to systemic administration of brain-derived GM1 to enhance GM1 levels in the brain via enzymatic conversion of polysialogangliosides into GM1 and to assess the neuroprotective potential of this approach. METHODS: We used sialidase from Vibrio cholerae (VCS) to convert GD1a, GD1b and GT1b gangliosides to GM1. VCS was infused by osmotic minipump into the dorsal third ventricle in mice over a 4-week period. After the first week of infusion, animals received MPTP injections (20 mg/kg, s.c., twice daily, 4 hours apart, for 5 consecutive days) and were euthanized 2 weeks after the last injection. RESULTS: VCS infusion resulted in the expected change in ganglioside expression with a significant increase in GM1 levels. VCS-treated animals showed significant sparing of striatal dopamine (DA) levels and substantia nigra DA neurons following MPTP administration, with the extent of sparing of DA neurons similar to that achieved with systemic GM1 administration. CONCLUSION: The results suggest that enzymatic conversion of polysialogangliosides to GM1 may be a viable treatment strategy for increasing GM1 levels in the brain and exerting a neuroprotective effect on the damaged nigrostriatal DA system.


Subject(s)
G(M1) Ganglioside/metabolism , Gene Expression Regulation/drug effects , Neuraminidase/administration & dosage , Neuraminidase/pharmacology , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Parkinson Disease/metabolism , Animals , Disease Models, Animal , Dopamine/metabolism , Infusions, Intraventricular , Male , Mice , Mice, Inbred C57BL , Neuraminidase/therapeutic use , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Parkinson Disease/pathology , Pars Compacta/drug effects , Pars Compacta/pathology , Vibrio cholerae/enzymology
3.
Brain Res ; 1354: 172-8, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20654591

ABSTRACT

Although the pathophysiological processes involved in dopamine (DA) neuron degeneration in Parkinson's disease (PD) are not completely known, apoptotic cell death has been suggested to be involved and can be modeled in DAergic cell lines using the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)). Recently, it has been suggested that histone deacetylase inhibitors (HDACIs) may reduce apoptotic cell death in various model systems. However, their utility in interfering with DA cell death remains unclear. The HDACIs sodium butyrate (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAHA) were tested for their ability to prevent MPP(+)-mediated cytotoxicity in human derived SK-N-SH and rat derived MES 23.5 cells. All three HDACIs at least partially prevented MPP(+)-mediated apoptotic cell death. The protective effects of these HDACIs coincided with significant increases in histone acetylation. These results suggest that HDACIs may be potentially neuroprotective against DA cell death and should be explored further in animal models of PD.


Subject(s)
1-Methyl-4-phenylpyridinium/pharmacology , Apoptosis/drug effects , Dopamine/metabolism , Histone Deacetylase Inhibitors/pharmacology , Histones/metabolism , Neurons/metabolism , Acetylation , Analysis of Variance , Animals , Butyric Acid/pharmacology , Cell Line , Cells, Cultured , Humans , Hydroxamic Acids/pharmacology , Immunohistochemistry , Nerve Degeneration/metabolism , Neurons/drug effects , Rats , Valproic Acid/pharmacology , Vorinostat
4.
Plant Mol Biol ; 60(5): 699-716, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16649107

ABSTRACT

Nicotine biosynthesis in Nicotiana tabacum is under genetic control by the A and B loci. Plants containing semi-dominant mutations at both the A and B loci (i.e. aabb genotype) have lower nicotine levels, reduced nicotine biosynthetic enzyme activities, and reduced mRNA levels of the corresponding biosynthetic genes. The A and B loci therefore appear to be coordinate regulators of several nicotine biosynthetic genes and define a group of co-regulated genes called the A-B regulon. To investigate the composition of genes in the A-B regulon, a fluorescent differential display (FDD) screen was used to randomly sample the transcriptomes of wild type and mutant aabb roots. This resulted in the isolation of 64 FDD clones, representing 49 unique genes or gene families. Four genes associated with nicotine biosynthesis were identified, whereas most of the other FDD clones were homologous with an assortment of stress response genes. Thirty-three genes or gene families showed reproducible aabb genotype effects, representing seven distinct mRNA expression patterns in response media treatments that increase the mRNA levels of known alkaloid biosynthetic genes. Thus, the A and B loci regulate the mRNA levels of some target genes differently than others. Eleven genes or gene families showed only treatment-specific effects, representing four mRNA accumulation patterns. These results indicate the A-B regulon is complex network of differentially expressed stress response genes, only a small subset of which are involved in nicotine biosynthesis.


Subject(s)
Gene Expression Regulation, Plant/genetics , Genes, Regulator/genetics , Nicotiana/genetics , Nicotine/biosynthesis , Acetates/pharmacology , Alkaloids/biosynthesis , Base Sequence , Cyclopentanes/pharmacology , Gene Expression Regulation, Plant/drug effects , Genes, Plant/genetics , Genotype , Molecular Sequence Data , Mutation , Oxylipins , Plant Growth Regulators/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Sequence Homology, Nucleic Acid , Nicotiana/drug effects , Nicotiana/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...